logo

CTSO

Cytosorbents·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

CTSO fundamentals

Cytosorbents (CTSO) released its earnings on Nov 13, 2025: revenue was 9.50M (YoY +1.17%), missed estimates; EPS was -0.04 (YoY +50.00%), beat estimates.
Revenue / YoY
9.50M
+1.17%
EPS / YoY
-0.04
+50.00%
Report date
Nov 13, 2025
CTSO Earnings Call Summary for Q3,2025
  • Revenue Growth: $9.5M Q3 (+10% YoY) driven by distributor and direct market expansion.
  • Profitability: 70% gross margin stability, $2M EBITDA improvement YoY.
  • FDA Progress: DrugSorb-ATR pre-submission meeting Q1 2026, potential approval mid-2026.
  • Cash Flow Management: $2.5M immediate liquidity, 10% workforce reduction to achieve Q1 2026 breakeven.
EPS
Revenue

Revenue & Expenses

CTSO has released its 2025 Q3 earnings report, with revenue of 9.48M, reflecting a YoY change of 10.12%, and net profit of -3.17M, showing a YoY change of -14.52%. The Sankey diagram below clearly presents CTSO's revenue sources and cost distribution.

Key Indicators

Cytosorbents (CTSO) key financial stats and ratios, covering profitability, financial health, and leverage.
Cytosorbents (CTSO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Cytosorbents (CTSO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cytosorbents (CTSO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Cytosorbents (CTSO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Cytosorbents (CTSO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield